Results 51 to 60 of about 29,631 (205)

Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility

Human Vaccines & Immunotherapeutics, 2021
The first vaccine against SARS-CoV-2 made available in Italy has been BNT162b2, the two-dose mRNA-based vaccine developed by Pfizer-BioNTech. The ASST Fatebenefratelli-Sacco hospital is located in one of the areas most affected by the pandemic, and to ...
Michele Gringeri, Giulia Mosini, Vera Battini, Gianluca Cammarata, Greta Guarnieri, Carla Carnovale, Emilio Clementi, Sonia Radice   +7 more
doaj   +1 more source

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults

Human Vaccines & Immunotherapeutics, 2023
In this phase 4 study we assessed boosting with fractional doses of heterologous COVID-19 vaccines in Brazilian adults primed with two doses of CoronaVac (Sinovac/Butantan, São Paulo, Brazil) at least 4 months previously.
Sue Ann Costa Clemens, Natalie Marchevsky, Sarah Kelly, Sally Felle, Ahmed Eldawi, Rupetha Rajasingam, Rawan Mahmud, Teresa Lambe, Merryn Voysey, Isabela Gonzalez, Eveline Pipolo Milan, Maria Cleonice Justino, Sagida Bibi, Parvinder Aley, Ralf Clemens, Andrew J. Pollard   +15 more
doaj   +1 more source

Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response

Human Vaccines & Immunotherapeutics, 2021
Vaccines against SARS-CoV-2 are known to be less immunogenic for some individuals, whereas others present notably high levels of antibody production.
Areti Tychala, Georgios Meletis, Eugenia Katsimpourlia, Ioanna Gkeka, Rodoula Dimitriadou, Eleni Sidiropoulou, Lemonia Skoura   +6 more
doaj   +1 more source

BNT162b2 covid-19 vaccine summary of findings table (RCT).

, 2023
BNT162b2 covid-19 vaccine summary of findings table (RCT).
Ameer Hohlfeld (6059231), Ntombifuthi Blose (17549600), Rudzani Muloiwa (546250), Natasha Gloeck (17549603), Yusentha Balakrishna (5797361), Andy Parrish (4955884), Karen Cohen (415951), Ruth Lancaster (17549606), Sumayyah Ebrahim (846653), Andy Gray (482821), Tamara Kredo (417544)   +10 more
core   +1 more source

The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster

Infection and Drug Resistance, 2022
Blanka Wolszczak Biedrzycka,1,2 Anna Bieńkowska,1,2 Elwira Smolińska-Fijołek,3 Grzegorz Biedrzycki,4 Justyna Dorf5 1Department of Psychology and Sociology of Health and Public Health, University of Warmia and Mazury in Olsztyn ...
Wolszczak Biedrzycka B, Bieńkowska A, Smolińska-Fijołek E, Biedrzycki G, Dorf J   +4 more
doaj  

SARS-CoV-2 S-RBD IgG & Neutralizing antibodies among different categories of health care workers post third dose BNT162b2 mRNA COVID-19 vaccine

Human Vaccines & Immunotherapeutics, 2023
Neutralizing antibodies (NTAb) play a significant role in preventing and protecting against SARS-CoV-2 virus infection. Identifying NTAb is undoubtedly imperative in understanding the immunity toward COVID-19 better.
Wan Muhammad Azfar Wan Shuaib, Izzatul Aliaa Badaruddin, Munirah Mansor, Sharifah Azura Salleh, Mohd Rohaizat Hassan, Steward Lindong, Shahril Nizam Samad, Hanita Othman   +7 more
doaj   +1 more source

BNT162b2 covid-19 vaccine summary of findings table (observational).

, 2023
BNT162b2 covid-19 vaccine summary of findings table (observational).
Ameer Hohlfeld (6059231), Ntombifuthi Blose (17549600), Rudzani Muloiwa (546250), Natasha Gloeck (17549603), Yusentha Balakrishna (5797361), Andy Parrish (4955884), Karen Cohen (415951), Ruth Lancaster (17549606), Sumayyah Ebrahim (846653), Andy Gray (482821), Tamara Kredo (417544)   +10 more
core   +1 more source

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients [PDF]

, 2022
Objective: Anti-CD20-treated patients are at risk of a reduced humoral immune response during the SARS-CoV-2 pandemic. Our aim was to compare the antibody response after two vaccinations with the mRNA vaccines BNT162b2 or mRNA-1273 in patients with ...
Kamber, Nicole, Helly Hammer, Hammer, Helly, Diem, Lara, Kamm, Christian P, Salmen, Anke, Hoepner, Robert, Robert Hoepner, Nicole Kamber, Stephen L. Leib, Friedli, Christoph, Andrew Chan, Kamm, Christian P., Christoph Friedli, Christian P. Kamm, Anke Salmen, Chan, Andrew, Leib, Stephen L., Lara Diem, Suter-Riniker, Franziska, Leib, Stephen L, Franziska Suter-Riniker   +21 more
core   +1 more source

Effectiveness of the first and the second dose of COVID-19 vaccines in Serbia during the first three months of rollout [PDF]

Srpski Arhiv za Celokupno Lekarstvo
Introduction/Objective. The main aim of this study was to assess COVID-19 vaccination effectiveness (VE) of BBIBP-CorV, Gam-COVID-Vac, BNT162b2, and ChAdOx1-nCoV-19 in Serbia during the first three months of rollout. Methods.
Đorđević Nataša, Matić Sanja, Milovanović Dragan, Stefanović Srđan, Popović Suzana, Todorović Danijela, Đurđević Predrag, Sazdanović Predrag, Antić Vasilije, Lončar Slavica, Bukumira Slavica, Radenković Marko, Šušteršić Tijana, Filipović Nenad, Baskić Dejan   +14 more
doaj   +1 more source

Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2

, 2023
We retrospectively analyzed 37 male healthy employees (mean age: 61±8 years) of the Pederzoli Hospital in Peschiera del Garda (Verona, Italy) who completed a primary vaccination cycle with the COVID-19 vaccine BNT162b2.
Giuseppe Lippi, Pighi, L, Gian Luca Salvagno, Simone De Nitto, De Nitto, S, Lippi, G, Salvagno, GL, Laura Pighi   +7 more
core   +1 more source